Lotus Bio-Technology Development EV/EBIT
The EV/EBIT (Enterprise Value to EBIT) of Lotus Bio-Technology Development (LBTD) as of Jul 21, 2026 is -0.04. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.04 — a change of -4.59% (higher).
Get this data via API
Financial Data API
EV/EBIT
-0.04
YoY
-4.59%
Last updated:
EV/EBIT (Enterprise Value to EBIT) of Lotus Bio-Technology Development is 2026 -0.04 . EV/EBIT (Enterprise Value to EBIT) of Lotus Bio-Technology Development was 2025 -0.04 . It decreases by -4.59% higher compared to the previous year.
The Lotus Bio-Technology Development EV/EBIT history
3 Years
10 Years
25 Years
Max
PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2011
0.00 base
Jan 1, 2012
0.00 base
Jan 1, 2013
0.00 base
Jan 1, 2014
-906.37 base
Jan 1, 2015
-1,841.83 base
Jan 1, 2016
-401.81 base
Jan 1, 2017
-84.46 base
| YEAR | PRICE-TO-EBIT |
|---|---|
| 2017 | -84.46 |
| 2016 | -401.81 |
| 2015 | -1,841.83 |
| 2014 | -906.37 |
| 2013 | - |
| 2012 | - |
| 2011 | - |
Access this data via the Eulerpool API
Lotus Bio-Technology Development Stock analysis
What does Lotus Bio-Technology Development do? Lotus Bio-Technology Development is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Lotus Bio-Technology Development stock
EV/EBIT (Enterprise Value to EBIT) of Lotus Bio-Technology Development is -0.04 in 2026.
Access this data via the Eulerpool API
Valuation — Lotus Bio-Technology Development
All Key Metrics — Lotus Bio-Technology Development
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth